表紙
市場調查報告書

骨髓發育不良症候群(MDS):2028年前的流行病學預測

Myelodysplastic Syndrome: Epidemiology Forecast to 2028

出版商 GlobalData 商品編碼 940507
出版日期 內容資訊 英文 40 Pages
訂單完成後即時交付
價格
骨髓發育不良症候群(MDS):2028年前的流行病學預測 Myelodysplastic Syndrome: Epidemiology Forecast to 2028
出版日期: 2020年05月29日內容資訊: 英文 40 Pages
簡介

本報告提供骨髓發育不良症候群(MDS)的相關調查,提供MDS趨勢和風險,流行病學的預測等資訊。

第1章 目錄

  • 表格的清單
  • 圖的清單

第2章 骨髓發育不良症候群:概要

  • 相關報告
  • 今後的報告

第3章 流行病學

  • 病的背景
  • 風險要素與並存症
  • 世界及歷史的趨勢
  • 預測調查手法
  • MDS的流行病學預測(2018年∼2028年)
  • 討論

第4章 附錄

  • 參考文獻
  • 關於作者
    • 流行病學者
    • 查讀者
    • 世界治療分析和流行病學總監
    • 全球主管和醫療保健業務和戰略執行副總裁
  • 關於GlobalData
  • 諮詢方式
  • 免責聲明
目錄
Product Code: GDHCER240-20

MDS are rare and a diverse group of clonal hematopoietic malignancies characterized by cytogenetic and molecular abnormalities, causing bone marrow failure and risk of progression to AML. MDS can affect people of any age but usually is most common in the 70 years and older population, with approximately 86% of newly diagnosed cases in older population over the age of 60 years. MDS patients present with symptoms related to peripheral cytopenias, though they may also be asymptomatic and routine laboratory findings might not detect anything significant except abnormal blood counts.

GlobalData epidemiologists used age- and sex-specific diagnosed incidence and prevalence rates to forecast the diagnosed incident and prevalent cases, taking into account the significant relationship between age and MDS incidence and prevalence. GlobalData epidemiologists applied country-specific incidence and prevalence rates of MDS, wherever available, to each country's population to obtain the number of estimated diagnosed incident and prevalent cases.

The following data describes epidemiology of MDS cases. In 2018, the 8MM had 90,332 diagnosed incident cases of MDS. This is expected to increase to 111,861 diagnosed incident cases by 2028, at an Annual Growth Rate (AGR) of 2.38%. This increase is partly attributed to the moderately rising trend in incidence in the 8MM, combined with underlying demographic changes in the respective markets. The 8MM will also see an increase in five-year diagnosed prevalent cases of MDS throughout the forecast period at an AGR of 2.35%, with 236,076 cases in 2018 and 291,581 in 2028. The development of more effective therapies, particularly for elderly patients, would improve survival from MDS.

Scope

  • Myelodysplastic syndrome (MDS) Epidemiology Report provides an overview of the risk factors and global trends of MDS in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and Canada).
  • This report also includes a 10-year epidemiological forecast for the following segmentations in ages 18 years and older across the 8MM: diagnosed incident cases and five-year diagnosed prevalent cases of MDS, and diagnosed incident cases of MDS/myeloproliferative neoplasms (MDS/MPN); diagnosed incident cases of MDS by subtypes (MDS with single lineage dysplasia, MDS with ring sideroblasts, MDS with multilineage dysplasia, MDS excess blasts, MDS with isolated del(5q), and MDS, unclassifiable), risk groups (very low risk, low risk, intermediate risk, high risk, and very high risk), primary/secondary, and mutations (IDH1, IDH2, SF3B1, ASXL1, TET2, RUNX1, JAK2, and TP53).
  • The MDS Epidemiology Report is written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

Reasons to Buy

The MDS Epidemiology series will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global MDS market.
  • Quantify patient populations in the global MDS market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the cancer subtypes that present the best opportunities for MDS therapeutics in each of the markets covered.
  • Understand magnitude of MDS market by biomarkers, risk group, and mutations.

Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2 Myelodysplastic Syndrome: Executive Summary

  • 2.1 Related Reports
  • 2.2 Upcoming Reports

3 Epidemiology

  • 3.1 Disease Background
  • 3.2 Risk Factors and Comorbidities
  • 3.3 Global and Historical Trends
  • 3.4 Forecast Methodology
    • 3.4.1 Sources
    • 3.4.2 Forecast Assumptions and Methods
  • 3.5 Epidemiological Forecast for MDS (2018-2028)
    • 3.5.1 Diagnosed Incident Cases of MDS
    • 3.5.2 Age-Specific Diagnosed Incident Cases of MDS
    • 3.5.3 Sex Specific Diagnosed Incident Cases of MDS
    • 3.5.4 Diagnosed Incident Cases of MDS/MPN
    • 3.5.5 Diagnosed Incident Cases of MDS by Subtype
    • 3.5.6 Diagnosed Incident Cases of Primary/Secondary MDS
    • 3.5.7 Diagnosed Incident Cases of MDS by Risk Group
    • 3.5.8 Diagnosed Incident Cases of MDS by Mutations
    • 3.5.9 Five-Year Diagnosed Prevalent Cases of MDS
  • 3.6 Discussion
    • 3.6.1 Epidemiological Forecast Insight
    • 3.6.2 Limitations of the Analysis
    • 3.6.3 Strengths of the Analysis

4 Appendix

  • 4.1 Bibliography
  • 4.2 About the Authors
    • 4.2.1 Epidemiologist
    • 4.2.2 Reviewers
    • 4.2.3 Global Director of Therapy Analysis and Epidemiology
    • 4.2.4 Global Head and EVP of Healthcare Operations and Strategy
  • 4.3 About GlobalData
  • 4.4 Contact Us
  • 4.5 Disclaimer

List of Tables

  • Table 1: Risk Factors and Comorbidities for MDS

List of Figures

  • Figure 1: 8MM, Diagnosed Incident Cases of MDS, Men and Women, Ages ≥18 Years, N, 2018
  • Figure 2: 8MM, Diagnosed Incidence Rates of MDS, Men and Women, Ages ≥18 Years, Cases per 100,000 Population, 2008-2028
  • Figure 3: Sources Used for Diagnosed Incident Cases of MDS
  • Figure 4: Sources Used for Diagnosed Incident Cases of MDS/MPN
  • Figure 5: Sources Used for Diagnosed Incident Cases of MDS Subtypes
  • Figure 6: Sources Used for Diagnosed Incident Cases of Primary/Secondary MDS
  • Figure 7: Sources Used for Five-Year Diagnosed Prevalent Cases of MDS
  • Figure 8: 8MM, Diagnosed Incident Cases of MDS, Men and Women, Ages ≥18 Years, N, 2018
  • Figure 9: 8MM, Age-Specific Diagnosed Incident Cases of MDS, Men and Women, Ages ≥18 Years, N, 2018
  • Figure 10: 8MM, Sex-Specific Diagnosed Incident Cases of MDS, Men and Women, Ages ≥18 Years, N, 2018
  • Figure 11: 8MM, Diagnosed Incident Cases MDS/MPN, Men and Women, Ages ≥18 Years, N, 2018
  • Figure 12: 8MM, Proportion of Diagnosed Incident Cases of MDS by Subtype, Men and Women, Ages ≥18 Years, N, 2018
  • Figure 13: 8MM, Proportion of Diagnosed Incident Cases of Primary/Secondary MDS, Men and Women, Ages ≥18 Years, 2018
  • Figure 14: 8MM, Diagnosed Incident Cases of MDS by Risk Group, Men and Women, Ages ≥18 Years, N, 2018
  • Figure 15: 8MM, Diagnosed Incident Cases of MDS by Mutation, Men and Women, Ages ≥18 Years, N, 2018
  • Figure 16: 8MM, Five-Year Diagnosed Prevalent Cases of MDS, Men and Women, Ages ≥18 Years, N, 2018